307 related articles for article (PubMed ID: 10353751)
1. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
Sieglová Z; Zilovcová S; Cermák J; Ríhová H; Brezinová D; Dvoráková R; Marková M; Maaloufová J; Sajdová J; Brezinová J; Zemanová Z; Michalová K
Leuk Res; 2004 Oct; 28(10):1013-21. PubMed ID: 15289012
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
4. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases.
Sashida G; Ohyashiki JH; Nakajima A; Sumi M; Kawakubo K; Tauchi T; Ohyashiki K
Clin Cancer Res; 2003 Apr; 9(4):1489-96. PubMed ID: 12684424
[TBL] [Abstract][Full Text] [Related]
5. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
6. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer.
Hirashima T; Komiya T; Nitta T; Takada Y; Kobayashi M; Masuda N; Matui K; Takada M; Kikui M; Yasumitu T; Ohno A; Nakagawa K; Fukuoka M; Kawase I
Anticancer Res; 2000; 20(3B):2181-7. PubMed ID: 10928174
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings.
Rigolin GM; Porta MD; Bugli AM; Castagnari B; Mauro E; Bragotti LZ; Ciccone M; Cuneo A; Castoldi G
Eur J Haematol; 2004 Nov; 73(5):351-8. PubMed ID: 15458514
[TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of telomerase activation and telomere length in head and neck cancer.
Patel MM; Parekh LJ; Jha FP; Sainger RN; Patel JB; Patel DD; Shah PM; Patel PS
Head Neck; 2002 Dec; 24(12):1060-7. PubMed ID: 12454944
[TBL] [Abstract][Full Text] [Related]
10. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma.
Garcia-Aranda C; de Juan C; Diaz-Lopez A; Sanchez-Pernaute A; Torres AJ; Diaz-Rubio E; Balibrea JL; Benito M; Iniesta P
Cancer; 2006 Feb; 106(3):541-51. PubMed ID: 16388518
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
13. [Telomere, telomerase and cytogenetic changes in myelodysplastic syndromes].
Ohyashiki K; Ohyashiki JH
Nihon Rinsho; 1998 May; 56(5):1328-32. PubMed ID: 9613146
[TBL] [Abstract][Full Text] [Related]
14. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
[TBL] [Abstract][Full Text] [Related]
16. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
17. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.
Engelhardt M; Albanell J; Drullinsky P; Han W; Guillem J; Scher HI; Reuter V; Moore MA
Clin Cancer Res; 1997 Oct; 3(10):1849-57. PubMed ID: 9815573
[TBL] [Abstract][Full Text] [Related]
18. Telomerase activity in myelodysplastic syndrome.
Fu C; Chen Z
Chin Med J (Engl); 2002 Oct; 115(10):1475-8. PubMed ID: 12490090
[TBL] [Abstract][Full Text] [Related]
19. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes.
Ohyashiki JH; Ohyashiki K; Fujimura T; Kawakubo K; Shimamoto T; Iwabuchi A; Toyama K
Cancer Res; 1994 Jul; 54(13):3557-60. PubMed ID: 8012981
[TBL] [Abstract][Full Text] [Related]
20. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
